<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jp2nlmx2.xsl?>
<?ConverterInfo.Version 2?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Bioinformatics</journal-id>
    <journal-id journal-id-type="iso-abbrev">Bioinformatics</journal-id>
    <journal-id journal-id-type="publisher-id">bioinformatics</journal-id>
    <journal-id journal-id-type="hwp">bioinfo</journal-id>
    <journal-title-group>
      <journal-title>Bioinformatics</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1367-4803</issn>
    <issn pub-type="epub">1367-4811</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">5018366</article-id>
    <article-id pub-id-type="doi">10.1093/bioinformatics/btw230</article-id>
    <article-id pub-id-type="publisher-id">btw230</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Applications Notes</subject>
        <subj-group subj-group-type="heading">
          <subject>Systems Biology</subject>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Combenefit: an interactive platform for the analysis and visualization of drug combinations</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Di Veroli</surname>
          <given-names>Giovanni Y.</given-names>
        </name>
        <xref ref-type="aff" rid="btw230-aff1">
          <sup>1</sup>
        </xref>
        <xref ref-type="aff" rid="btw230-aff2">
          <sup>2</sup>
        </xref>
        <xref ref-type="corresp" rid="btw230-cor1">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Fornari</surname>
          <given-names>Chiara</given-names>
        </name>
        <xref ref-type="aff" rid="btw230-aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Dennis</given-names>
        </name>
        <xref ref-type="aff" rid="btw230-aff3">
          <sup>3</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mollard</surname>
          <given-names>Séverine</given-names>
        </name>
        <xref ref-type="aff" rid="btw230-aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Bramhall</surname>
          <given-names>Jo L.</given-names>
        </name>
        <xref ref-type="aff" rid="btw230-aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Richards</surname>
          <given-names>Frances M.</given-names>
        </name>
        <xref ref-type="aff" rid="btw230-aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Jodrell</surname>
          <given-names>Duncan I.</given-names>
        </name>
        <xref ref-type="aff" rid="btw230-aff1">
          <sup>1</sup>
        </xref>
      </contrib>
      <aff id="btw230-aff1"><sup>1</sup>CRUK Cambridge Institute, University of Cambridge, Cambridge, UK</aff>
      <aff id="btw230-aff2"><sup>2</sup>Early Clinical Development, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, UK</aff>
      <aff id="btw230-aff3"><sup>3</sup>Bioinformatics, Oncology Innovative Medicines, AstraZeneca, Cambridge, UK</aff>
    </contrib-group>
    <author-notes>
      <corresp id="btw230-cor1">*To whom correspondence should be addressed</corresp>
      <fn id="btw230-FM1">
        <p>Associate Editor: Jonathan Wren</p>
      </fn>
    </author-notes>
    <pub-date pub-type="ppub">
      <day>15</day>
      <month>9</month>
      <year>2016</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>25</day>
      <month>4</month>
      <year>2016</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>25</day>
      <month>4</month>
      <year>2016</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
    <volume>32</volume>
    <issue>18</issue>
    <fpage>2866</fpage>
    <lpage>2868</lpage>
    <history>
      <date date-type="received">
        <day>14</day>
        <month>12</month>
        <year>2015</year>
      </date>
      <date date-type="rev-recd">
        <day>05</day>
        <month>4</month>
        <year>2016</year>
      </date>
      <date date-type="accepted">
        <day>20</day>
        <month>4</month>
        <year>2016</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author 2016. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2016</copyright-year>
      <license xlink:href="http://creativecommons.org/licenses/by/4.0/" license-type="creative-commons">
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <abstract>
      <p><bold>Motivation:</bold> Many drug combinations are routinely assessed to identify synergistic interactions in the attempt to develop novel treatment strategies. Appropriate software is required to analyze the results of these studies.</p>
      <p><bold>Results:</bold> We present Combenefit, new free software tool that enables the visualization, analysis and quantification of drug combination effects in terms of synergy and/or antagonism. Data from combinations assays can be processed using classical Synergy models (Loewe, Bliss, HSA), as single experiments or in batch for High Throughput Screens. This user-friendly tool provides laboratory scientists with an easy and systematic way to analyze their data. The companion package provides bioinformaticians with critical implementations of routines enabling the processing of combination data.</p>
      <p><bold>Availability and Implementation:</bold> Combenefit is provided as a Matlab package but also as standalone software for Windows (<ext-link ext-link-type="uri" xlink:href="http://sourceforge.net/projects/combenefit/">http://sourceforge.net/projects/combenefit/</ext-link>).</p>
      <p>
        <bold>Contact:</bold>
        <email>Giovanni.DiVeroli@cruk.cam.ac.uk</email>
      </p>
      <p><bold>Supplementary information:</bold><ext-link ext-link-type="uri" xlink:href="http://bioinformatics.oxfordjournals.org/lookup/suppl/doi:10.1093/bioinformatics/btw230/-/DC1">Supplementary data</ext-link> are available at <italic>Bioinformatics</italic> online.</p>
    </abstract>
    <counts>
      <page-count count="3"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec>
    <title>1 Introduction</title>
    <p>The combination of drugs is an important strategy to treat various diseases. The goal is to increase efficacy and, through the avoidance of overlapping toxicity, improve the therapeutic index of treatment (<xref rid="btw230-B10" ref-type="bibr">Long <italic>et al.</italic>, 2014</xref>). At the discovery stage, research often focuses on the identification of synergistic target effects using <italic>in vitro</italic> systems (<xref rid="btw230-B7" ref-type="bibr">Lehár <italic>et al.</italic>, 2009</xref>; <xref rid="btw230-B14" ref-type="bibr">Roemer and Boone, 2013</xref>; <xref rid="btw230-B15" ref-type="bibr">Sun <italic>et al.</italic>, 2013</xref>). Large scale combination screens testing multiple pairwise combinations of drugs across different concentration ranges and cell lines are being performed with increasing frequency (<xref rid="btw230-B5" ref-type="bibr">He <italic>et al.</italic>, 2015</xref>; <xref rid="btw230-B6" ref-type="bibr">Held <italic>et al.</italic>, 2013</xref>; <xref rid="btw230-B11" ref-type="bibr">Mathews Griner <italic>et al.</italic>, 2014</xref>). Typically, the dose–response data generated during these experiments are then analyzed in terms of synergistic or antagonistic effects. Free software were developed in the past but these are limited in terms of data handling and available options, particularly given high throughput screens (HTS) requirements (<ext-link ext-link-type="uri" xlink:href="http://www.combosyn.com/">http://www.combosyn.com/</ext-link>; <xref rid="btw230-B3" ref-type="bibr">Dressler <italic>et al.</italic>, 1999</xref>; <xref rid="btw230-B13" ref-type="bibr">Prichard and Shipman, 1990</xref>). Two recent commercial software packages offer advanced features such as automated analyses, choice from a variety of models, quality curve-fitting, variety of graphical displays and metrics quantification (Chalice <ext-link ext-link-type="uri" xlink:href="http://cwr.horizondiscovery.com">http://cwr.horizondiscovery.com</ext-link>; Genedata <ext-link ext-link-type="uri" xlink:href="https://www.genedata.com">https://www.genedata.com</ext-link>). There is a lack of free, advanced, scalable, software for the analysis of drug combinations. As part of the growing effort in the search of effective combinations, we present here Combenefit (‘<italic>Combinations Benefit</italic>’), a new software tool that enables the visualization, analysis and quantification of drug combination effects, in terms of synergy and/or antagonism, for single combination experiments but also HTS as per commercial packages (<xref ref-type="table" rid="btw230-T1">Table 1</xref>).
<table-wrap id="btw230-T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Features of available software for drugs combinations analyses. L: Loewe, B: Bliss, H: HSA, DR: Dose–response curve, M: Matrix view, C: contours, S: surfaces, I: Isobolograms, SM: synergy mapped to dose–response surfaces, F: Fa related curves, see (<xref rid="btw230-B2" ref-type="bibr">Chou, 2010</xref>). Note: we have not included CombiTool (<xref rid="btw230-B3" ref-type="bibr">Dressler <italic>et al.</italic>, 1999</xref>) because it does not appear to be available anymore</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Combenefit</th><th rowspan="1" colspan="1">Chalice<sup>TM</sup></th><th rowspan="1" colspan="1">Genendata Screener<sup>®</sup></th><th rowspan="1" colspan="1">CompuSyn</th><th rowspan="1" colspan="1">MacSynergy™ II</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Available</td><td rowspan="1" colspan="1">Free</td><td rowspan="1" colspan="1">Commercial</td><td rowspan="1" colspan="1">Commercial</td><td rowspan="1" colspan="1">Free</td><td rowspan="1" colspan="1">Free</td></tr><tr><td rowspan="1" colspan="1">Source code</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Spreadsheet</td></tr><tr><td rowspan="1" colspan="1">Replicates</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">Yes</td></tr><tr><td rowspan="1" colspan="1">Fitting (Hill model)</td><td rowspan="1" colspan="1">3 params</td><td rowspan="1" colspan="1">3 params</td><td rowspan="1" colspan="1">3 params + baseline</td><td rowspan="1" colspan="1">2 params (no max)</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Synergy models</td><td rowspan="1" colspan="1">L,B,H (+planned)</td><td rowspan="1" colspan="1">L,B,H and 2 others</td><td rowspan="1" colspan="1">L,B,H</td><td rowspan="1" colspan="1">L based</td><td rowspan="1" colspan="1">B</td></tr><tr><td rowspan="1" colspan="1">Scores/metrics</td><td rowspan="1" colspan="1">Several</td><td rowspan="1" colspan="1">Several</td><td rowspan="1" colspan="1">Several</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td></tr><tr><td rowspan="1" colspan="1">Graphics</td><td rowspan="1" colspan="1">DR,M,C,S,SM</td><td rowspan="1" colspan="1">DR,M,C,I</td><td rowspan="1" colspan="1">DR,M,C,I</td><td rowspan="1" colspan="1">DR,I,F</td><td rowspan="1" colspan="1">C,S</td></tr><tr><td rowspan="1" colspan="1">Data input</td><td rowspan="1" colspan="1">File</td><td rowspan="1" colspan="1">File</td><td rowspan="1" colspan="1">File</td><td rowspan="1" colspan="1">Manual</td><td rowspan="1" colspan="1">Manual</td></tr><tr><td rowspan="1" colspan="1">HTS suitable</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">No</td></tr></tbody></table></table-wrap></p>
  </sec>
  <sec>
    <title>2 General overview</title>
    <p>Combenefit implements a surface approach, where <italic>in vitro</italic> experimental data is compared to mathematical models of dose–responses for non-synergistic combinations (also termed additive or independent combinations; <xref rid="btw230-B4" ref-type="bibr">Greco and Bravo, 1995</xref>). The three classical models, namely the Loewe (<xref rid="btw230-B9" ref-type="bibr">Loewe and Muchnick, 1926</xref>; <xref rid="btw230-B8" ref-type="bibr">Loewe, 1953</xref>), the Bliss (<xref rid="btw230-B1" ref-type="bibr">Bliss, 1939</xref>; <xref rid="btw230-B17" ref-type="bibr">Webb, 1963</xref>) and the Highest Single Agent (HSA; <xref rid="btw230-B11" ref-type="bibr">Mathews Griner <italic>et al.</italic>, 2014</xref>; <xref rid="btw230-B16" ref-type="bibr">Tan <italic>et al.</italic>, 2012</xref>) models have been incorporated. These models have been used extensively in the literature, with different fields having their preference and sometimes alternative names for these same models (<xref rid="btw230-B4" ref-type="bibr">Greco and Bravo, 1995</xref>; <xref rid="btw230-B12" ref-type="bibr">Odds, 2003</xref>). It is important to use these models in a consistent way and to provide results in the context of the model used. Additionally, our own group is currently developing a new general model which, together with any other future feature, will be incorporated into Combenefit.</p>
    <p>The approach implemented in Combenefit can be summarized as follows (<xref ref-type="fig" rid="btw230-F1">Fig. 1a</xref>). The experimental dose–response surface that delineates combination effects in concentration space, is first read by the software as a matrix of % of the control value across concentrations. Single agent effects are extracted from this data and fitted with a dose response curve. Based on the two single agent dose response curves, a model-based combination dose–response surface is derived. This surface provides a ‘reference’ dose–response surface for a non-synergistic (additive/independent) combination, whose characteristics are determined by the selected model (Loewe, Bliss, etc.). The experimental combination dose response surface is then compared to the model-generated one, resulting in a synergy distribution in concentration space. This synergy distribution can be further summarized via various metrics as described below.
<fig id="btw230-F1" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Analysis and visualization of drug combinations with Combenefit. (<bold>a</bold>) Illustration of analysis principle. (<bold>b</bold>) Illustration of automated processing (Color version of this figure is available at <italic>Bioinformatics</italic> online.)</p></caption><graphic xlink:href="btw230f1p"/></fig>
</p>
  </sec>
  <sec>
    <title>3 Using Combenefit</title>
    <p>The software is available as a standalone application for Windows or as a Matlab package. The standalone application can be installed automatically and is then directly accessed through its own icon. The Matlab package needs to be saved in a dedicated folder which is then accessed via Matlab by calling the <italic>Combenefit</italic> routine contained in the package. Laboratory scientists can quickly and easily analyze their data using either version. Bioinformaticians can use the code provided in the Matlab package to facilitate their own projects involving drugs combinations.</p>
    <sec>
      <title>3.1 Typical analysis</title>
      <p>A typical analysis is performed as follows. Upon completion of experiments, the results of a specific combination (including replicates if available) are saved in .xls files (the data is ordered with the first drug in columns and the second in rows; a template is provided). Once Combenefit is launched, the project folder containing all experimental .xls files is selected (<xref ref-type="fig" rid="btw230-F1">Fig. 1b</xref>). Then, one or more reference models can be selected. Other options and graphical outputs can be chosen as per requirements/preferences. The graphical outputs consist of: (i) the single agent dose response data and its fitting, (ii) the combination dose response (Four different displays), (iii) the model-generated reference combination dose response, i.e. the prediction of effect if the drugs are not synergistic (Three different displays) and (iv) the resulting synergy distribution (Three different displays). Additionally, a fourth graphic mapping the synergy distribution onto the dose–response surface can also be displayed to facilitate interpretation. All figures, as well as corresponding data, fitting parameters and synergy metrics (see below) can be saved in the project folder. Figures are saved as high quality .png or .pdf files which can be directly used in publications. A user’s guide with step-by-step guidance for installing and running the software is available online.</p>
    </sec>
    <sec>
      <title>3.2 Metrics and batch analysis</title>
      <p>The analyses described above result in a synergy distribution for the combination being processed. To facilitate comparison across experiments, or for HTS applications, it is useful to summarize the resulting synergy and/or antagonism distribution using one or more metrics. Combenefit provides a set of metrics (or scores) which captures information about the synergy distribution. These include metrics such as the maximum synergy, the integrated and the weighted integrated synergy and concentration value at which synergy is most dense (for a full list of metrics and their formulation, please see the Supplementary Material).</p>
      <p>During HTS, large volumes of combinations and cell lines are investigated using automated technology. Combenefit can be used to analyze the large amount of data derived with these screens. Using Combenefit, the user selects the folder containing all experiments (each in an individual sub-folder) and then selects the ‘Batch Analysis’ option. Upon running the analysis, Combenefit will batch process in a sequential way all the folders. The results of the analysis are summarized in a table containing all the experiments in rows and the metrics in columns. Typically, the highest hits are then visually inspected using Combenefit’s graphical outputs to improve understanding of the data and prioritize drug combinations. Combenefit has been recently used to generate the AstraZeneca dataset (∼11 500 combinations) provided for the current AstraZeneca-Sanger Drug Combination Prediction DREAM challenge (<ext-link ext-link-type="uri" xlink:href="http://dreamchallenges.org/">http://dreamchallenges.org/</ext-link>).</p>
      <p>In summary, we have described the overall implementation and functioning of Combenefit, new software which offers advanced graphical capabilities and allows for model-based quantification of drug combinations in single and high-throughput settings. We hope that this new tool will continue to improve and will help many scientists in a variety of fields involving combination data analyses.</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="PMC_1" content-type="local-data">
      <caption>
        <title>Supplementary Data</title>
      </caption>
      <media mimetype="text" mime-subtype="html" xlink:href="supp_32_18_2866__index.html"/>
      <media xlink:role="associated-file" mimetype="application" mime-subtype="msword" xlink:href="supp_btw230_supplementary_material.docx"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <title>Acknowledgements</title>
    <p>We acknowledge all support and feedback from <italic>Combenefit</italic> users.</p>
  </ack>
  <sec>
    <title>Funding</title>
    <p>This work has been supported by <funding-source>the Cancer Research UK</funding-source> grant <award-id>C14303/A17197</award-id>.</p>
    <p><italic>Conflict of Interest:</italic> none declared.</p>
  </sec>
  <ref-list>
    <title>References</title>
    <ref id="btw230-B1">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bliss</surname><given-names>C.I.</given-names></name></person-group> (<year>1939</year>) <article-title>The toxicity of poisons applied jointly</article-title>. <source>Ann. Appl. Biol</source>., <volume>26</volume>, <fpage>585</fpage>–<lpage>615</lpage></mixed-citation>
    </ref>
    <ref id="btw230-B2">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>T.C.</given-names></name></person-group> (<year>2010</year>) <article-title>Drug combination studies and their synergy quantification using the Chou–Talalay method</article-title>. <source>Cancer Res</source>., <volume>70</volume>, <fpage>440</fpage>–<lpage>446</lpage>.<pub-id pub-id-type="pmid">20068163</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B3">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dressler</surname><given-names>V</given-names></name></person-group><etal/> (<year>1999</year>) <article-title>CombiTool–a new computer program for analyzing combination experiments with biologically active agents</article-title>. <source>Comput. Biomed. Res</source>., <volume>32</volume>, <fpage>145</fpage>–<lpage>160</lpage>.<pub-id pub-id-type="pmid">10337496</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B4">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greco</surname><given-names>W.R.</given-names></name><name><surname>Bravo</surname><given-names>G.,P.J.C.</given-names></name></person-group>, (<year>1995</year>) <article-title>The search for synergy: a critical review from a response surface perspective</article-title>. <source>Pharmacol. Rev</source>., <volume>47</volume>, <fpage>331</fpage>–<lpage>385</lpage>.<pub-id pub-id-type="pmid">7568331</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B5">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>S</given-names></name></person-group><etal/> (<year>2015</year>) <article-title>Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection</article-title>. <source>Sci. Transl. Med</source>., <volume>7</volume>, <fpage>1</fpage>–<lpage>11</lpage>.</mixed-citation>
    </ref>
    <ref id="btw230-B6">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Held</surname><given-names>M. a</given-names></name></person-group><etal/> (<year>2013</year>) <article-title>Genotype-selective combination therapies for melanoma identified by high-throughput drug screening</article-title>. <source>Cancer Discov</source>., <volume>3</volume>, <fpage>52</fpage>–<lpage>67</lpage>.<pub-id pub-id-type="pmid">23239741</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B7">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehár</surname><given-names>J</given-names></name></person-group><etal/> (<year>2009</year>) <article-title>Synergistic drug combinations tend to improve therapeutically relevant selectivity</article-title>. <source>Nat. Biotechnol</source>., <volume>27</volume>, <fpage>659</fpage>–<lpage>666</lpage>.<pub-id pub-id-type="pmid">19581876</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B8">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loewe</surname><given-names>S.</given-names></name></person-group> (<year>1953</year>) <article-title>The problem of synergism and antagonism of combined drugs</article-title>. <source>ArzneimiettelForschung</source>, <volume>3</volume>, <fpage>286</fpage>–<lpage>290</lpage>.</mixed-citation>
    </ref>
    <ref id="btw230-B9">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loewe</surname><given-names>S.</given-names></name><name><surname>Muchnick</surname><given-names>H.</given-names></name></person-group> (<year>1926</year>) <article-title>Effect of combinations: mathematical basis of problem</article-title>. <source>Arch. Exp. Pathol. Pharmacol</source>., <volume>114</volume>, <fpage>313</fpage>–<lpage>326</lpage>.</mixed-citation>
    </ref>
    <ref id="btw230-B10">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>G.V</given-names></name></person-group><etal/> (<year>2014</year>) <article-title>Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma</article-title>. <source>Nat. Commun</source>., <volume>5</volume>, <fpage>5694</fpage>.<pub-id pub-id-type="pmid">25452114</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B11">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathews Griner</surname><given-names>L.A</given-names></name></person-group><etal/> (<year>2014</year>) <article-title>High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells</article-title>. <source>Proc. Natl. Acad. Sci. USA</source>, <volume>111</volume>, <fpage>2349</fpage>–<lpage>2354.</lpage><pub-id pub-id-type="pmid">24469833</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B12">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Odds</surname><given-names>F.C.</given-names></name></person-group> (<year>2003</year>) <article-title>Synergy, antagonism, and what the chequerboard puts between them</article-title>. <source>J. Antimicrob. Chemother</source>., <volume>52</volume>, <fpage>1.</fpage><pub-id pub-id-type="pmid">12805255</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B13">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prichard</surname><given-names>M.N.</given-names></name><name><surname>Shipman</surname><given-names>C.</given-names></name></person-group> (<year>1990</year>) <article-title>A three-dimensional model to analyze drug-drug interactions</article-title>. <source>Antiviral Res</source>., <volume>14</volume>, <fpage>181</fpage>–<lpage>205</lpage>.<pub-id pub-id-type="pmid">2088205</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B14">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roemer</surname><given-names>T.</given-names></name><name><surname>Boone</surname><given-names>C.</given-names></name></person-group> (<year>2013</year>) <article-title>Systems-level antimicrobial drug and drug synergy discovery</article-title>. <source>Nat. Chem. Biol</source>., <volume>9</volume>, <fpage>222</fpage>–<lpage>231</lpage>.<pub-id pub-id-type="pmid">23508188</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B15">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name></person-group><etal/> (<year>2013</year>) <article-title>High-throughput methods for combinatorial drug discovery</article-title>. <source>Sci. Trans. Med</source>., <volume>5</volume>, <fpage>205rv1</fpage>.</mixed-citation>
    </ref>
    <ref id="btw230-B16">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>X</given-names></name></person-group><etal/> (<year>2012</year>) <article-title>Systematic identification of synergistic drug pairs targeting HIV</article-title>. <source>Nat. Biotechnol</source>., <volume>30</volume>, <fpage>1125</fpage>–<lpage>1130</lpage>.<pub-id pub-id-type="pmid">23064238</pub-id></mixed-citation>
    </ref>
    <ref id="btw230-B17">
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>J.L.</given-names></name></person-group> (<year>1963</year>) <article-title>Effect of more than one inhibitor</article-title>. <source>Enzyme Metab. Inhib</source>, <volume>1</volume>, <fpage>66</fpage>–<lpage>79</lpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
